ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ADMA • US0008991046

16.43 USD
+0.49 (+3.07%)
At close: Feb 6, 2026
16.45 USD
+0.02 (+0.12%)
After Hours: 2/6/2026, 8:16:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall ADMA gets a fundamental rating of 7 out of 10. We evaluated ADMA against 524 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. This makes ADMA very considerable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ADMA was profitable.
  • In the past year ADMA had a positive cash flow from operations.
  • ADMA had negative earnings in 4 of the past 5 years.
  • In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 36.83%, ADMA belongs to the top of the industry, outperforming 98.86% of the companies in the same industry.
  • ADMA's Return On Equity of 48.57% is amongst the best of the industry. ADMA outperforms 98.66% of its industry peers.
  • ADMA has a Return On Invested Capital of 25.76%. This is amongst the best in the industry. ADMA outperforms 98.66% of its industry peers.
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROIC 25.76%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • ADMA's Profit Margin of 42.87% is amongst the best of the industry. ADMA outperforms 98.09% of its industry peers.
  • The Operating Margin of ADMA (34.19%) is better than 97.33% of its industry peers.
  • The Gross Margin of ADMA (54.71%) is better than 76.72% of its industry peers.
  • ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
  • ADMA has more shares outstanding than it did 1 year ago.
  • ADMA has more shares outstanding than it did 5 years ago.
  • ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ADMA has an Altman-Z score of 18.59. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 18.59, ADMA belongs to the top of the industry, outperforming 89.12% of the companies in the same industry.
  • ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.78, ADMA belongs to the top of the industry, outperforming 93.70% of the companies in the same industry.
  • ADMA has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • ADMA has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: ADMA underperforms 64.31% of its industry peers.
  • Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Altman-Z 18.59
ROIC/WACC2.91
WACC8.85%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 7.13 indicates that ADMA has no problem at all paying its short term obligations.
  • The Current ratio of ADMA (7.13) is better than 70.80% of its industry peers.
  • A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
  • ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 46.56% of its industry peers.
Industry RankSector Rank
Current Ratio 7.13
Quick Ratio 3.65
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.86% over the past year.
  • Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 27.62%.
  • ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%

3.2 Future

  • Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 33.00% on average per year.
  • ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.50% yearly.
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 30.43, ADMA can be considered very expensive at the moment.
  • 93.13% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.92. ADMA is around the same levels.
  • With a Price/Forward Earnings ratio of 18.00, ADMA is valued on the expensive side.
  • ADMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 94.47% of the companies in the same industry.
  • ADMA is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.78, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.43
Fwd PE 18
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 93.70% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
  • 91.41% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 96.29
EV/EBITDA 21.74
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • ADMA has a very decent profitability rating, which may justify a higher PE ratio.
  • ADMA's earnings are expected to grow with 33.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.57
PEG (5Y)N/A
EPS Next 2Y35.12%
EPS Next 3Y33.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMA BIOLOGICS INC

NASDAQ:ADMA (2/6/2026, 8:16:54 PM)

After market: 16.45 +0.02 (+0.12%)

16.43

+0.49 (+3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-02
Inst Owners93.5%
Inst Owner Change-3.3%
Ins Owners2.35%
Ins Owner Change-0.33%
Market Cap3.91B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts82.22
Price Target26.18 (59.34%)
Short Float %8.13%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-5.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)0%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)1.19%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE 30.43
Fwd PE 18
P/S 8
P/FCF 96.29
P/OCF 60.18
P/B 9.07
P/tB 9.15
EV/EBITDA 21.74
EPS(TTM)0.54
EY3.29%
EPS(NY)0.91
Fwd EY5.56%
FCF(TTM)0.17
FCFY1.04%
OCF(TTM)0.27
OCFY1.66%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.57
PEG (5Y)N/A
Graham Number4.69
Profitability
Industry RankSector Rank
ROA 36.83%
ROE 48.57%
ROCE 32.61%
ROIC 25.76%
ROICexc 29.27%
ROICexgc 29.53%
OM 34.19%
PM (TTM) 42.87%
GM 54.71%
FCFM 8.31%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.78
Debt/EBITDA 0.4
Cap/Depr 304.79%
Cap/Sales 4.99%
Interest Coverage 15.23
Cash Conversion 37.13%
Profit Quality 19.39%
Current Ratio 7.13
Quick Ratio 3.65
Altman-Z 18.59
F-Score7
WACC8.85%
ROIC/WACC2.91
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.34%
EPS Next 2Y35.12%
EPS Next 3Y33.64%
EPS Next 5Y33%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.85%
Revenue Next 2Y22.49%
Revenue Next 3Y22.24%
Revenue Next 5Y21.5%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.1%
EBIT Next 3Y45.85%
EBIT Next 5Y36.27%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A

ADMA BIOLOGICS INC / ADMA FAQ

What is the fundamental rating for ADMA stock?

ChartMill assigns a fundamental rating of 7 / 10 to ADMA.


What is the valuation status of ADMA BIOLOGICS INC (ADMA) stock?

ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.


How profitable is ADMA BIOLOGICS INC (ADMA) stock?

ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.


What is the financial health of ADMA BIOLOGICS INC (ADMA) stock?

The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.